YM-254890

• UNSPSC Description:

  YM-254890 is a selective Gαq/11 protein inhibitor isolated from Chromobacterium sp. YM-254890 shows no inhibition of other G protein subtypes. YM-254890 inhibits platelet aggregation induced by ADP by blocking the P2Y1 signal transduction pathway, with an IC50 value below 0.6 μM[1][2].

• Target Antigen:

  P2Y Receptor

• Type:

  Natural Products

• Related Pathways:

  GPCR/G Protein

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/ym-254890.html

• Purity:

  99.0

• Solubility:

  DMSO : 50 mg/mL (ultrasonic)

• Smiles:

  CN([C@@H](C)C(N[C@@H]([C@H](OC([C@@H](NC(C)=O)[C@@H](C(C)C)O)=O)C(C)C)C(N(C)[C@@H]([C@H](OC)C)C(O[C@@H]1C)=O)=O)=O)C([C@H](C)NC(C(N(C([C@@H](CC2=CC=CC=C2)OC([C@H]1NC(C)=O)=O)=O)C)=C)=O)=O

• Molecular Weight:

  960.08

• References & Citations:

  [1]Taniguchi M, et al. YM-254890, a novel platelet aggregation inhibitor produced by Chromobacterium sp. QS3666. J Antibiot (Tokyo). 2003 Apr;56(4):358-63.|[2]Zhang H, et al. Structure-activity relationship and conformational studies of the natural product cyclic depsipeptides YM-254890 and FR900359. Eur J Med Chem. 2018 Aug 5;156:847-860.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  568580-02-9